Positive top-line results from a Phase III randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip have been released.
Israel’s Teva Pharmaceuticals Industries (NYSE: TEVA) and US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) are jointly developing fasinumab as part of a global collaboration agreement signed in September 2016.
Teva’s shares gained 3.66% to 8,361 shekels in Tel Aviv trading, while Regeneron edged up 2.03% to $369.20 by mid-morning in New York,
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze